secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2022-01-31T23:59:59+00:00
Accession:  0001568276-22-000302
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics appoints Robyn Hunter to Board, cures Nasdaq audit committee compliance
--------------------------------------------------------------------------------

- Robyn Hunter appointed as independent director and chair of Audit and Compliance Committee, effective Jan 28, 2022.
- Hunter is CFO of Fortress Biotech; adds financial and life sciences expertise to the Board.
- Appointment resolves non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) for audit committee composition.
- Board remains majority independent following her appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000156827622000302/0001568276-22-000302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000156827622000302/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001568276-22-000302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer